Stories about Employee retention

Subscribe to Employee retention

05.06.2020 – 07:25

UCB Pharma
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

Brussels, Belgium (ots/PRNewswire) - - Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure - Staccato® Alprazolam could be a potential solution for ...

more
30.04.2020 – 10:22

Brenntag AG

Brenntag publishes new sustainability report

Find more information on our corporate website.
One document
more
02.04.2020 – 15:34

UCB Pharma
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab, UCB's FcRn targeting ...

more
21.11.2019 – 07:45

creditshelf
creditshelf continues to expand its platform business in Q3 2019

Frankfurt am Main (ots) - - Revenue up 59.0% to EUR 2,460.3 thousand - EBIT improves year-on-year to EUR minus 4,188.6 thousand despite investments in expanding the platform - Further milestones in implementation of growth strategy achieved - Management adjusts outlook for fiscal year 2019 creditshelf Aktiengesellschaft, a pioneer in the area of digital SME finance in Germany, published its figures for Q3 2019 today. The ...

more
10.10.2019 – 09:38

UCB Pharma
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

Brussels and Cambridge, Massachusetts (ots/PRNewswire) - - Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - ...

more
13.11.2018 – 07:30

Wirecard AG
Wirecard and givve enhance digital benefits to improve loyalty amongst hundreds of thousands of employees

Aschheim (Munich) (ots) - - Wirecard has already issued almost 300,000 employee cards for over 8,500 givve corporate customers - givve's acquisition by Up group opens up a new range of deployment scenarios in the field of loyalty and incentives Wirecard, the global innovation leader for digital financial technology, ...

more

1